Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Valeant (Two Dermatological Products)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portfolio of two generic dermatology products. The portfolio is comprised of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, used for the topical treatment of acne vulgaris and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, used for the topical treatment of multiple actinic or solar keratoses.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 2150 Saint Elzéar Boulevard
  • Laval
  • Quebec, Quebec H7L 4A8
  • Canada

Valeant (Two Dermatological Products) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Valeant (Two Dermatological Products)‘s full profile, request access.

Request full access to PitchBook

Valeant (Two Dermatological Products) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Valeant (Two Dermatological Products)‘s full profile, request access.

Request full access to PitchBook